



## **Othera Pharmaceuticals Elects Hans Mueller to Board**

Exton, PA, October 12, 2005 – Othera Pharmaceuticals Inc., a privately-held specialty pharmaceutical company developing proprietary drugs to treat or prevent the three leading causes of blindness, announced today that it has elected Hans Mueller, Ph.D. to its board of directors.

With a long career in the pharmaceutical industry dating back to 1969, Dr. Mueller most recently served as the Senior Vice President of Global Business Development for Wyeth Pharmaceuticals from 1993 to 2004.

“Dr. Mueller brings a wealth of large pharmaceutical company experience, particularly in the areas of strategy, licensing and collaboration to our drug development program as we anticipate having five phase 2 clinical trials underway in 2006,” said David S. Joseph, Chairman and CEO of Othera. “His industry knowledge will aid our pursuit of ophthalmic pharmaceutical corporate alliances.”

Dr. Mueller received his Ph.D. in Actuarial Science and Mathematical Statistics. He is a graduate of Harvard Business School’s Advanced Management Program and a Lecturer at the University of Bern, Switzerland. His prior employment included Sandoz, now known as Novartis, and Nova Pharmaceuticals Inc., now known as Scios Inc. which is part of Johnson & Johnson.

### **About Othera**

Othera Pharmaceuticals, Inc. is a privately-held, ophthalmic pharmaceutical company located in Exton, Pennsylvania. Othera is developing proprietary drugs to treat or prevent the three leading causes of blindness and vision impairment in the world – cataracts, age-related macular degeneration (AMD) and glaucoma. The Company’s lead drug, OT-551, is a potent antioxidant eyedrop formulation to prevent the development of cataracts and AMD. Othera’s novel beta-blocker drug, OT-730, is an eyedrop treatment for glaucoma. For information please visit our website at [www.othera.com](http://www.othera.com).

###

### **Contact:**

Julie Huang  
Financial Dynamics  
212-850-5628  
jhuang@fd-us.com